Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 7/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12143361 | 0.91 | APLNR (0.42) | ADORA1APLNRCA12CA2CA1 | |
| SCHEMBL23042768 | 0.89 | TDP1 (0.42) | ADORA1APLNRCA12CA2CA14 | |
| SCHEMBL15757814 | 0.88 | ADORA1 (0.38) | ADORA1APLNRCA12CA2GBA1 | |
| SCHEMBL23818338 | 0.88 | TDP1 (0.43) | ADORA1APLNRCA12CA2CA1 | |
| SCHEMBL14258502 | 0.88 | PLK1 (0.35) | ADORA1APLNRCA12CA2CA14 | |
| SCHEMBL13014750 | 0.86 | APLNR (0.37) | ADORA1APLNRCA12CA2GBA1 | |
| SCHEMBL2743023 | 0.86 | APLNR (0.37) | ADORA1APLNRCA12CA2GBA1 | |
| SCHEMBL14679532 | 0.85 | APLNR (0.38) | ADORA1APLNRCA12CA2CA1 | |
| SCHEMBL17655693 | 0.85 | APLNR (0.38) | ADORA1APLNRCA12CA2CA1 | |
| SCHEMBL15765901 | 0.84 | APLNR (0.38) | ADORA1APLNRCA12CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11311400-B2 | Methods for making conjugates from disulfide-containing proteins | NOVARTIS AG (CH) | 2022-04-26 | — | — | US | disclosed |
| US-20200253768-A1 | METHODS FOR MAKING CONJUGATES FROM DISULFIDE-CONTAINING PROTEINS | NOVARTIS AG (CH) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311400-B2 | Methods for making conjugates from disulfide-containing proteins | PDIA6, PTMS, PDIA3 | ADORA1 4740/4885APLNR 2367/4885CA12 536/4885 |
| US-20200253768-A1 | METHODS FOR MAKING CONJUGATES FROM DISULFIDE-CONTAINING PROTEINS | PDIA6, PTMS, PDIA3 | ADORA1 4740/4885APLNR 2367/4885CA12 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.